BMRN Stock - BioMarin Pharmaceutical Inc.
Unlock GoAI Insights for BMRN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B |
| Gross Profit | $2.27B | $1.89B | $1.59B | $1.38B | $1.34B |
| Gross Margin | 79.7% | 78.0% | 76.0% | 74.5% | 71.8% |
| Operating Income | $484.21M | $185.77M | $160.97M | $-82,341,000 | $-43,440,000 |
| Net Income | $426.86M | $167.65M | $141.56M | $-64,080,000 | $854.03M |
| Net Margin | 15.0% | 6.9% | 6.8% | -3.5% | 45.9% |
| EPS | $2.25 | $0.89 | $0.76 | $-0.35 | $4.75 |
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Visit WebsiteEarnings History & Surprises
BMRNEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 18, 2026 | $0.94 | — | — | — |
Q4 2025 | Oct 27, 2025 | $-0.15 | $0.12 | +180.0% | ✓ BEAT |
Q3 2025 | Aug 4, 2025 | $0.86 | $1.44 | +67.2% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $0.94 | $1.13 | +20.2% | ✓ BEAT |
Q1 2025 | Feb 19, 2025 | $0.54 | $0.92 | +70.4% | ✓ BEAT |
Q4 2024 | Oct 29, 2024 | $0.78 | $0.91 | +16.7% | ✓ BEAT |
Q3 2024 | Aug 5, 2024 | $0.36 | $0.96 | +168.3% | ✓ BEAT |
Q2 2024 | Apr 24, 2024 | $0.31 | $0.71 | +127.7% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $0.44 | $0.49 | +11.4% | ✓ BEAT |
Q4 2023 | Nov 1, 2023 | $0.46 | $0.46 | 0.0% | = MET |
Q3 2023 | Jul 31, 2023 | $0.47 | $0.54 | +14.9% | ✓ BEAT |
Q2 2023 | Apr 26, 2023 | $0.43 | $0.60 | +39.5% | ✓ BEAT |
Q1 2023 | Feb 27, 2023 | $-0.07 | $0.36 | +614.3% | ✓ BEAT |
Q4 2022 | Oct 26, 2022 | $0.37 | $0.45 | +21.6% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $0.43 | $0.59 | +37.2% | ✓ BEAT |
Q2 2022 | Apr 27, 2022 | $0.38 | $0.55 | +44.7% | ✓ BEAT |
Q1 2022 | Feb 23, 2022 | $0.03 | $0.03 | +0.4% | ✓ BEAT |
Q4 2021 | Oct 27, 2021 | $0.11 | $0.18 | +63.6% | ✓ BEAT |
Q3 2021 | Jul 28, 2021 | $0.30 | $0.53 | +76.7% | ✓ BEAT |
Latest News
Frequently Asked Questions about BMRN
What is BMRN's current stock price?
What is the analyst price target for BMRN?
What sector is BioMarin Pharmaceutical Inc. in?
What is BMRN's market cap?
Does BMRN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BMRN for comparison